ZYNE(Delisted)
Zynerba PharmaceuticalsยทNASDAQ
--
--(--)
ZYNE Profile
Zynerba Pharmaceuticals, Inc.
The leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders
80 W. Lancaster Avenue, Suite 300, Devon, PA 19333
--
Zynerba Pharmaceuticals, Inc. was incorporated in Delaware on January 31, 2007 as AllTranz, Inc., and changed its name to Zynerba Pharmaceuticals, Inc., in August 2014. The Company is a ten-year-old specialty pharmaceutical company dedicated to the development and marketing of proprietary next-generation synthetic cannabinoid treatments for transdermal drug delivery. Its management team has extensive experience, and has successively developed patch and gel transdermal drug delivery products, which have been approved by the regulatory authorities, which is a successful history of commercialization. The company is evaluating two patent-protected product candidates, ZYN002 and ZYN001.
